Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Share-based Compensation (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Share-based Compensation for 4 consecutive years, with $891000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 73.15% to $891000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $8.2 million, a 39.67% decrease, with the full-year FY2024 number at $12.7 million, down 13.23% from a year prior.
  • Share-based Compensation was $891000.0 for Q3 2025 at Century Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q3 2023 to a low of $891000.0 in Q3 2025.
  • A 4-year average of $2.9 million and a median of $2.8 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 59.54% in 2023, then tumbled 73.15% in 2025.
  • Century Therapeutics' Share-based Compensation stood at $2.7 million in 2022, then soared by 30.38% to $3.6 million in 2023, then fell by 25.32% to $2.7 million in 2024, then tumbled by 66.5% to $891000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Share-based Compensation are $891000.0 (Q3 2025), $2.2 million (Q2 2025), and $2.4 million (Q1 2025).